Mylan has exited its investment in Biocon by selling its entire 5.64% stake for ₹3,679 crore through block deals, according to thehindubusinessline.com. The transaction took place recently, leading to a more than 6% rise in Biocon's shares on the stock market.
The stake sale was executed via block deals, a mechanism that allows large investors to buy or sell substantial quantities of shares without impacting the market price significantly. Mylan's exit marks a strategic divestment from Biocon, which has been a notable player in the pharmaceutical sector. The sale's completion was confirmed by market sources and reflected in the stock price movement.
This divestment is significant in the pharmaceutical sector, where Biocon has been a key player in biosimilars and generic drugs. The ₹3,679 crore deal is among the larger block transactions in the sector recently, reflecting shifting investment patterns. Biocon's share price jump of over 6% post-sale indicates strong market confidence despite Mylan's exit.
Following the stake sale, Biocon's shares surged by more than 6%, highlighting investor optimism. The transaction value of ₹3,679 crore underscores the scale of Mylan's exit. Biocon continues to be a major entity in the pharmaceutical industry, with its stock performance closely watched by investors and analysts.